Cullinan Therapeutics, Inc. (CGEM) Research

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

Market snapshot

Symbol
CGEM
Price
$15.03
Day change
+4.09%
Market cap
$923.7M
P/E ratio
-4.03x
52-week range
5.68-16.74
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Next earnings
in 2 months
Analyst price target
$31.00

Peer companies

  • ADC Therapeutics S.A. (ADCT)
  • Bicycle Therapeutics plc (BCYC)
  • CeriBell, Inc. (CBLL)
  • Enhabit, Inc. (EHAB)
  • Standard BioTools Inc. (LAB)
  • Neumora Therapeutics, Inc. Common Stock (NMRA)
  • Omeros Corporation (OMER)
  • RAPT Therapeutics, Inc. (RAPT)

Recent insider activity

  • Rosenberg Anthony — A-Award (25319 shares) on 2026-06-16
  • Meek David D. — A-Award (25319 shares) on 2026-06-16
  • Webster Stephen W — A-Award (25319 shares) on 2026-06-16
  • Allen Andrew R — A-Award (21781 shares) on 2026-06-16
  • Thistle Mary — A-Award (25319 shares) on 2026-06-16

Open Cullinan Therapeutics, Inc. (CGEM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.